Everest Medicines Limited (HKG:1952)
Hong Kong · Delayed Price · Currency is HKD 27.00
-3.20 (-10.60%)
May 28, 2026, 9:29 AM HKT
Everest Medicines Market Cap
Everest Medicines has a market cap or net worth of 10.61 billion as of May 27, 2026. Its market cap has decreased by -33.76% in one year.
Market Cap
10.61B
Enterprise Value
8.61B
Revenue
1.90B
Ranking
n/a
PE Ratio
n/a
Stock Price
27.00
Market Cap Chart
Since October 9, 2020, Everest Medicines's market cap has decreased from 20.64B to 10.61B, a decrease of -48.57%. That is a compound annual growth rate of -11.13%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| May 27, 2026 | 10.61B | -18.76% |
| Dec 31, 2025 | 13.06B | -16.21% |
| Dec 31, 2024 | 15.59B | 132.87% |
| Dec 29, 2023 | 6.70B | 24.60% |
| Dec 30, 2022 | 5.37B | -47.96% |
| Dec 31, 2021 | 10.33B | -47.98% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Oct 9, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Ascletis Pharma | 16.57B |
| Zai Lab | 16.38B |
| Ascentage Pharma Group International | 15.33B |
| CStone Pharmaceuticals | 12.82B |
| Nanjing Leads Biolabs | 12.76B |
| HBM Holdings | 10.54B |
| CARsgen Therapeutics Holdings | 9.43B |
| Alphamab Oncology | 9.06B |